Mifepristone Controversy

FDA Opens Mifepristone Safety Review as Republicans Move to Curb Mail and Telehealth Access

Confirmed in a Sept. 19 letter, the inquiry weighs contested complication claims against decades of safety data, with potential limits on remote access under review.